Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Revolutionizing the Approach to Spine Surgery We are more than a medical technolo...
Revolutionizing the Approach to Spine Surgery ...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
BioTelemetry, Inc. is the leading remote medical technology company focused on the...
BioTelemetry, Inc. is the leading remote medica...
Akari is a biopharmaceutical company focused on developing inhibitors of acute and...
Akari is a biopharmaceutical company focused on...
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet pa...
OPKO Health, Inc. is a diversified healthcare c...
Sienna Biopharmaceuticals, Inc. is a clinicalâstage biopharmaceutical company fo...
Sienna Biopharmaceuticals, Inc. is a clinicalâ...
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused o...
BioXcel Therapeutics, Inc. is a clinical stage ...
Join the National Investor Network and get the latest information with your interests in mind.